Rasna Therapeutics, Inc. filed its 10-K/A on Jun 10, 2022 for the period ending Sep 30, 2021. In this report its auditor, Marcum LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0173 USD | +121.79% | +121.79% | +124.68% |
1st Jan change | Capi. | |
---|---|---|
+124.68% | 13.35M | |
-1.69% | 103B | |
+7.67% | 101B | |
+4.40% | 23.07B | |
-11.61% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.75% | 16.94B | |
+6.63% | 14.07B | |
+37.93% | 12.35B |
- Stock Market
- Equities
- RASP Stock
- News Actavia Life Sciences, Inc.
- Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt